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AbstrAct
Introduction Optimal targets for systemic oxygenation 
in paediatric critical illness are unknown. Observational 
data indicate that high levels of arterial oxygenation are 
associated with poor outcomes in resuscitation of the 
newborn and in adult critical illness. Within paediatric 
intensive care units (PICUs), staff prevent severe 
hypoxia wherever possible, but beyond this there is no 
consensus. Practice varies widely with age, diagnosis, 
treating doctor and local or national guidelines followed, 
though peripheral blood oxygen saturations (SpO
2) of 
>95% are often targeted. The overall aim of this pilot 
study is to determine the feasibility of performing a 
randomised trial in critically ill children comparing 
current practice of liberal SpO
2 targets with a more 
conservative target.
Methods and analysis Oxy-PICU is a pragmatic, 
open, pilot randomised controlled trial in infants and 
children requiring mechanical ventilation and receiving 
supplemental oxygen for abnormal gas exchange 
accepted for emergency admission to one of three 
participating UK PICUs. The study groups will be either 
a conservative SpO
2 target of 88%–92% (inclusive) or 
a liberal SpO2 target of >94%. Infants and children who 
fulfil all inclusion criteria and none of the exclusion 
criteria will be randomised 1:1 by a secure web-based 
system to one of the two groups. Baseline demographics 
and clinical status will be recorded as well as 
daily measures of oxygenation and organ support. 
Discharge outcomes will also be recorded. In addition 
to observational data, blood and urine samples will 
be taken to identify biochemical markers of oxidative 
stress. Outcomes are targeted at assessing study 
feasibility with a primary outcome of adequate study 
recruitment (target: 120 participants).
Ethics and dissemination The trial received Health 
Research Authority approval on 1 June 2017 (16/
SC/0617). Study findings will be disseminated in 
national and international conferences and peer-
reviewed journals.
trial registration number NCT03040570.
IntroductIon
The optimal targets for systemic oxygenation 
in paediatric critical illness are unknown. 
Intensive care staff prevent severe hypoxia 
wherever possible, but beyond this there 
is no consensus. Practice varies widely with 
age, diagnosis and treating doctor.1 2 This 
uncertainty about the optimal oxygenation 
target is illustrated by the variance in national 
guidelines in even the most common cause of 
acute infant respiratory distress: respiratory 
syncytial virus bronchiolitis. The US Amer-
ican Academy of Pediatrics recommends a 
peripheral blood oxygen saturation (SpO2) 
target >90%, whereas the Scottish Intercol-
legiate Guidelines Network recommend 
SpO2 >94%.
3 
Oxygenation targets have become a ‘hot 
topic’ for clinical trials because of obser-
vational data suggesting that high levels of 
arterial oxygenation are associated with poor 
outcomes in resuscitation of the newborn, 
adult critical illness, myocardial infarction, 
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strengths and limitations of this study
 ► This is the first randomised trial to compare 
conservative and liberal systemic oxygenation 
targets in mechanically ventilated children.
 ► As this is a pilot study, without a formal power 
calculation, outcomes of clinical significance should 
be treated as hypothesis-generating only.
 ► If deemed to be feasible, the outcomes and 
evaluation of processes of this study will inform a 
larger appropriately powered definitive study.
 ► The pragmatic design of this study will allow us to 
assess the ability of clinical staff to adhere to the 
target treatment groups.
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postcardiac arrest and possibly also in respiratory failure.4 
When added to the known risks of severe hypoxia, a 
‘U-shaped’ relationship between arterial oxygenation and 
risk of death emerges.5 6 We have recently completed a 
systematic review of the paediatric literature addressing 
this issue, and although the data are scarce, the same 
pattern of increased risk and both high and low levels 
of arterial oxygenation has been observed.7 Our recent 
cohort study of 7410 critically ill children also demon-
strated a ‘U-shaped’ relationship between admission 
arterial oxygen tension and survival. This pattern persists 
after adjustment for case-mix (including congenital 
cyanotic heart disease) and indicators of physiological 
severity. This complex relationship between oxygenation 
and outcome may reflect the balance between harm 
from hypoxia at one end of the oxygenation spectrum 
(low SpO2) and a combination of increased oxygen free 
radical damage and iatrogenic injury from more aggres-
sive treatments at the other (high SpO2).
6
The lack of evidence indicating the safest oxygen 
level for a critically ill child needs investigation. Around 
19 000 such children are admitted to paediatric inten-
sive care units (PICUs) in the UK annually. Around 
75% receive artificial support for ventilation in some 
form. The primary aim of this artificial ventilation is to 
support blood oxygen values at a safe level. However, 
since the optimal level is unknown, clinicians typically 
default to targeting physiologically normal or even 
supranormal values. With other variables during critical 
illness, this approach of ‘normalisation of physiology’ 
is known to be either harmful or of no benefit.8–11 In 
neonatal and critically ill adult patients, the choice of 
oxygen targets are known to influence survival rates, 
lengths of stay and costs. Three large randomised 
studies in extreme preterm infants compared lower 
(85%–89%) with higher oxygen targets (91%–95%).12 
Unexpectedly, an increased risk of death (1.45; 95% CI 
1.15 to 1.84; P=0.002) was seen with the lower oxygen 
targets. In contrast, recent pilot data in adult critical 
illness demonstrate a trend towards the opposite effect: 
that is, reduced mortality with lower oxygenation targets 
in the sickest patients: relative risk 0.49 (95% CI 0.20 
to 1.17; P=0.10).13 Similarly, harmful effects of supple-
mental oxygen have been demonstrated in adults with 
ST elevation myocardial infarction.14 15 In October 
2016, a single-centre study in adults was stopped early 
because of a significant survival advantage: absolute 
risk reduction for intensive care unit mortality (8.6%, 
1.7%–15% P=0.01) in the conservative oxygenation 
group.16 Even prior to these data, there has been a move 
in adult intensive care towards lower oxygen targets, 
for example, SpO2 88%–95%.
4
The only paediatric trial data—in non-critically ill 
children with bronchiolitis—demonstrate equivalent 
safety of a peripheral oxygen saturation (SpO2) target 
of >90% when compared with >94%. Later hospital 
discharges were seen with the higher target (ratio of 
length of stay: 1.28, 95% CI 1.09 to 1.50, P=0.003).17
Current practice favours very liberal oxygen targets. 
We have conducted an analysis of around 7 million SpO2 
values averaged over 5 s in a single PICU: 30% of recorded 
values were 100% and >60% were >95%.18
study aim
The overall aim of this study is to determine if it is feasible 
to perform a safe, adequately powered and affordable 
definitive randomised controlled trial in critically ill chil-
dren comparing current practice of liberal targets for 
systemic oxygen levels with more conservative targets. 
The underlying hypothesis of a definitive trial is that the 
harm of interventions to raise arterial oxygen saturation 
to >94% exceeds the benefits of these interventions.
study objectives
 ► To test the willingness of clinicians to screen, recruit 
and randomise eligible patients.
 ► To estimate the recruitment rate.
 ► To test, following randomisation, delivery of and 
adherence to, the intervention and demonstrate sepa-
ration between the groups.
 ► To test acceptability of the deferred consenting proce-
dures and participant information.
 ► To test follow-up for the identified, potential, 
patient-centred primary and other important 
secondary outcome measures and for adverse event 
(AE) reporting.
 ► To inform final selection of a patient-centred primary 
outcome measure.
 ► To estimate the characteristics (eg, SD) of the selected 
patient-centred primary outcome measure to inform 
sample size estimation.
 ► To inform content and time needed for final data 
collection.
 ► To investigate the feasibility of collecting samples suit-
able for estimation of ischaemic/oxidative injury and 
antioxidant status.
MEthods And AnAlysIs
study design and setting
Oxy-PICU is a pragmatic, open, pilot randomised 
controlled trial in infants and children accepted for emer-
gency admission to participating PICUs. Study recruit-
ment will be at three PICUs and their local PICU transport 
teams representing typical configurations for UK PICUs 
(general or combined ICUs in general academic medical 
centres or within stand-alone children’s hospitals).
trial population and eligibility criteria
Infants and children receiving treatment at a partici-
pating site who fulfil all of the inclusion criteria and none 
of the exclusion criteria below:
Inclusion criteria
 ► Less than 16 years and more than 38 weeks’ corrected 
gestational age.
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 ► Emergency admission accepted to a PICU requiring 
mechanical ventilation within first 6 hours of face-to-
face contact with PICU staff or transport team.
 ► Receiving supplemental oxygen for abnormal gas 
exchange.
Exclusion criteria
 ► Death perceived as imminent.
 ► Brain pathology/injury as primary reason for admis-
sion (eg, traumatic brain injury, post-cardiac arrest, 
stroke and convulsive status epilepticus without 
aspiration).
 ► Known pulmonary hypertension.
 ► Known or suspected sickle cell disease.
 ► Known or suspected uncorrected congenital cardiac 
disease.
 ► End-of-life care plan in place with limitation of 
resuscitation.
 ► Receiving long-term mechanical ventilation prior to 
this admission (non-invasive ventilation (NIV) or inva-
sive ventilation (IV)).
 ► Recruited to Oxy-PICU in a previous admission.
screening and randomisation
Potentially eligible infants and children will be screened 
against the inclusion/exclusion criteria by transport team 
and PICU staff supported by the Oxy-PICU trial team 
(figure 1). Randomisation will then follow a ‘research 
without prior consent’ model. Randomisation will occur 
as soon as eligibility has been confirmed with the aim of 
commencing treatment as soon as possible within the 
first 6 hours of the infant or child being in face-to-face 
contact with the PICU or transport staff. Participants 
will be randomly allocated (1:1) to either the conserva-
tive (88%–92%) or liberal (>94%) oxygen target group 
by a computer-generated dynamic procedure (minimis-
ation) with a random component. Minimisation will be 
performed on: age (<12 months/≥12 months), study 
site and primary reason for admission (lower respiratory 
tract infection vs other); and degree of abnormality of gas 
exchange: Saturation/FiO2 (S/F) ratio <221 with positive 
end expiratory pressure >5 versus other. Randomisation 
will be via a secure web-based system.
Prerandomisation and postrandomisation care
Prior to randomisation, all care will be determined by the 
clinical team primarily responsible for the child’s treat-
ment and care. Once randomised, all care other than that 
intended to achieve trial target SpO2 will be determined 
by the clinical team.
consent procedures
Patients receiving mechanical support to ventilation 
requiring supplemental oxygen will most often need 
oxygen treatment started in a life-threatening emer-
gency, where any delay in commencing treatment will be 
detrimental. This will make any attempt to obtain fully 
informed consent from parents/legal representatives 
during an emergency inappropriate and cause additional 
anxiety to families who are already distressed by their 
child’s illness. Consent will therefore follow a deferred 
consent model following previous work and guidelines in 
this setting.19 20
Once notified of the recruitment of a patient to the 
study, a delegated member of the site research team will 
approach the parents/legal representatives as soon as 
practically and appropriately possible after randomi-
sation to discuss the study and provide a participant 
information sheet (PIS) (usually within 24–48 hours of 
randomisation). If the participant has been discharged 
or has died prior to their parents/legal representa-
tives being approached, then the parents/legal repre-
sentatives will be approached by an appropriate team 
member at a later point and will be provided with a 
standard PIS or a specific PIS for bereaved parents/
guardians (B-PIS).
A consent form will be provided including a state-
ment that participation is voluntary and that consent 
can be withdrawn at any time without consequence 
(online supplementary material 1). Parents/legal repre-
sentatives will be allowed time to read the PIS (or B-PIS) 
and have an opportunity to ask any questions they may 
have about their child’s participation in Oxy-PICU. 
Deferred consent can be sought from parents/legal 
representatives following the death of their child and 
prior to their departure from the hospital if appropriate.
For participants who are discharged alive from 
PICU but have not been consented prior to discharge 
from the hospital, a study team member will call their 
parents/legal representative within five working days 
of discharge. For all participants discharged prior to 
consent, their parents/legal representatives will subse-
quently be sent a covering letter, personalised by the 
most appropriate clinical team member, and a copy of 
the relevant PIS and consent form by post 4 weeks after 
randomisation. If there is no response after 4 weeks 
of sending the initial letter, a follow-up letter along 
with the appropriate PIS will be sent to the family. 
Both letters will explain how to opt-out of the study 
and provide telephone contact details if parents/legal 
representatives wish to discuss the study with a member 
of the site research team. The second letter will provide 
the same information as the first letter. In addition, 
this letter will also confirm that if no consent form is 
received within 4 weeks of receipt of the letter, then the 
participant’s data (samples collected will be destroyed) 
will be included in the study unless the family notify the 
site research team otherwise.19
Parents/legal representatives can refuse to give consent 
(non-consent) or withdraw from Oxy-PICU at any time 
during the study. All data collected up to the point of with-
drawal will be retained and included in the study anal-
ysis. In order to monitor non-consent, a minimal dataset 
will be collected for each parent/legal representative 
approached but not consented. In the case of non-con-
sent/withdrawal from the study, any samples collected 
will be destroyed.
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Figure 1 Trial schema of eligibility, randomisation and study intervention to discharge from PICU. FiO2, fraction of 
inspired oxygen; HFNO, high flow humidified oxygen; IV, invasive ventilation; MAP, mean airway pressure; NIV, non-invasive 
ventilation; PEEP, positive end expiratory pressure; PICU, paediatric intensive care unit; SpO2, peripheral oxygen saturations.
consent questionnaire
For parents/legal representatives who are approached 
for consent in person, as part of the PIS, parents/legal 
representatives will be provided with information about 
the option to complete a questionnaire regarding their 
views on the consenting procedures for the Oxy-PICU 
pilot study (online supplementary material 2). Question-
naires will be used to highlight specific concerns related 
to the consent procedure or conduct of hospital staff and 
will be used to inform future research design.
trial intervention
Liberal group
Participants allocated to the liberal oxygenation group 
will receive supplemental oxygen and ventilator settings 
at the discretion of the treating clinical team with the 
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Table 1 Data collection time points for enrolled participants
Time point
Baseline Daily PICU discharge
Age Ventilation mode* Date of discharge
Gender Interventions for 
organ support† 
Survival status
Weight Hourly 
SpO2 values‡ 
Discharge 
diagnosis
Acute diagnosis – –
Chronic diagnosis – –
Severity of gas 
exchange
– –
Cause of respiratory 
failure
– –
PIM2r score – –
*Ventilation mode including FiO2 and mean airway pressure.
†Including use of vasoactive drugs, ECMO, blood transfusion, 
renal support and neuromuscular blocker or sedative drug 
infusions.
‡Hourly SpO2 values for first 24 hours, then 4 hourly until day 
6 postrandomisation and 12 hourly thereafter until the end of 
mechanical ventilation.
ECMO, extracorporeal membrane oxygenation; FiO2, fraction 
of inspired oxygen; PICU, paediatric intensive care unit; PIM2r, 
paediatric index of mortality 2 recalibated; SpO2, peripheral oxygen 
saturations.
aim of maintaining peripheral oxygen saturations >94%. 
This will be continued until all ventilator support (deliv-
ered invasively or non-invasively) has been discontinued 
during this PICU admission. All other care (including 
antimicrobial therapy, fluid therapy, analgesic and seda-
tive agents and bronchodilator therapy) will be deter-
mined by the clinical team primarily responsible for the 
participant’s care.
Conservative group
Participants allocated to the conservative oxygenation 
group will receive supplemental oxygen and ventilator 
settings at the discretion of the treating clinical team 
with the aim of maintaining peripheral oxygen satu-
rations between 88% and 92% (inclusive). This will 
be continued until all ventilator support (delivered 
invasively or non-invasively) has been discontinued 
during this PICU admission. All other care will be 
determined by the clinical team primarily responsible 
for the participant’s care.
data collection and follow-up
Detailed guidance for the collection of data will be 
provided in the trial-specific standard operating 
procedure. All data items will be objectively defined 
according to relevant national and international 
guidelines. Data will be collected at baseline prior to 
randomisation, daily and at discharge from PICU as 
detailed in table 1. Patients will be followed-up until 
discharge from a participating PICU. Data entered 
onto the secure trial database will undergo validation 
checks for completeness, accuracy and consistency of 
data. Queries on incomplete, inaccurate or inconsis-
tent data will be sent to the research team at partici-
pating sites for resolution.
sample collection
Samples of blood and urine will be collected to assess 
for possible mechanisms of oxidative injury. Blood 
from indwelling invasive lines will be sampled within 
24 hours of randomisation and again up to 72 hours 
postrandomisation (or immediately prior to removal 
of suitable invasive sampling lines in patients with 
an anticipated shorter length of stay). Plasma from 
samples of 1–1.5 mL of whole blood will be analysed 
for malondialdehyde, ischaemia-modified albumin 
and total antioxidant status. Leucocyte hypoxia-in-
ducible factor-1 alpha mRNA expression will also be 
estimated. Other markers of plasma and leucocyte 
oxidative stress may be investigated. Urine samples 
will also be taken at the same time points (within 
24 hours and up to 72 hours postrandomisation) to 
discover biomarkers of oxidative stress using metabo-
lomics and proteomic analyses.
Adverse events
All infants and children eligible for Oxy-PICU are 
critically ill and due to the complexity of their condi-
tion are at increased risk of experiencing AEs. Many 
of these events are expected as a result of the infant/
child’s medical condition and standard treatment 
received in the PICU and may not be related to partic-
ipation in the trial. Consequently, any AEs occurring 
as a result of the infant/child’s medical condition or 
standard critical care treatment will not be reported. 
Pre-existing conditions do not qualify as AEs unless 
they worsen but should be documented in the infant/
child’s medical notes. AEs that occur between rando-
misation and PICU discharge must be recorded in the 
participant’s medical notes and on the Oxy-PICU case 
report form. Those meeting the definition of a serious 
AE (SAE) must, in addition, be recorded in the SAE 
log and reported to the Intensive Care National 
Audit & Research Centre (ICNARC) Clinical Trials 
Unit (CTU), using the trial specific Oxy-PICU SAE 
Reporting Form, by fax within 24 hours of observing 
or learning of the SAE.
trial monitoring and oversight
The ICNARC CTU will conduct at least one moni-
toring visit to participating sites during the course of 
the pilot study. The trial will be supervised by the Trial 
Steering Committee (TSC), which will be chaired by 
an independent member and will include at least two 
additional independent members and a service user 
representative.
Safety will be monitored by the Data Monitoring and 
Ethics Committee (DMEC) throughout the trial period. 
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box outcome measures of the oxy-PIcu feasibility study
Primary outcome measure
 ► Number of eligible patients recruited per site per month.
secondary outcome measures
 ► Proportion of parents/legal representatives refusing deferred 
consent.
 ► Proportion of eligible patients randomised (target 50%).
 ► Distribution of time to randomisation.
 ► Proportion of systemic oxygen saturations within the target range 
in each group.
 ► Proportion of patients in each arm requiring other treatments 
influencing tissue oxygen delivery (blood transfusion and inotropic 
support).
 ► Characteristics and completeness of potential primary endpoints for 
a definitive study including: length of ventilation, length of paediatric 
intensive care unit  (PICU) stay, PICU mortality  and days of organ 
specific support.
 ► Observed adverse events.
 ► Time taken for data collection and entry.
 ► Distribution of markers of ischaemia and antioxidant status.
All members of the DMEC will be independent of both 
the Oxy-PICU Trial Management Group and the TSC. The 
DMEC will operate under the DAMOCLES Charter17 18 
and will report to the TSC, making recommendations on 
the continuation, or not, of the trial. The ICNARC CTU 
will be responsible for the day-to-day management of the 
trial and will act as custodian of the data. The ICNARC 
CTU will ensure that all SAEs are reported, as appro-
priate, to the REC.
outcome measures
As this is a pilot study outcome measures for the study will 
be focused on assessing the study feasibility for a larger 
scale definitive study as noted in box below.
statistics
Power calculation
The Oxy-PICU pilot study is primarily set-up to test the feasi-
bility of the protocol to recruit eligible patients. Therefore, 
there is no primary outcome to be compared between the 
two groups and, hence, a usual power calculation to deter-
mine sample size is not appropriate. Instead, the sample 
size has been determined to be adequate to estimate critical 
parameters to be tested to a necessary degree of precision. 
Based on available data from PICANet, it is anticipated that 
the participating sites will recruit approximately 4–10 chil-
dren per month, providing a total of approximately 120 chil-
dren in 6 months.
Statistical analysis
Descriptive analysis will be conducted to assess the objectives 
of Oxy-PICU. All analyses will be carried out on an inten-
tion-to-treat basis. Screening data will be reported by site and 
randomisation, and consent data will be reported by site and 
treatment group. Baseline demographic and clinical data as 
detailed in table 1 will be summarised by group and overall. 
Continuous variables will be summarised as mean (SD) and 
median (IQR) while categorical variables will be summarised 
as number (percentage).
Adherence to the intervention will be reported as:
 ► Time in SpO2 target range (hours) – mean (SD) and 
median (IQR) will be reported by treatment group.
 ► Percentage of time points SpO2 measurements in 
range by treatment group.
Daily organ support procedures will be presented 
graphically by plotting the percentage of patients in each 
group receiving each recorded support procedure. Daily 
interventions received will be presented graphically by 
plotting the mean (SD) of each intervention.
A comparison of outcomes by treatment group will be 
reported for the following outcome measures:
 ► Length of PICU stay.
 ► Length of IV.
 ► Length of NIV.
 ► Ventilator-free days at day 30.
 ► Duration of organ support.
 ► PICU mortality.
Ethical compliance
The Oxy-PICU pilot study will be conducted in accor-
dance with the approved trial protocol, ICH Good Clin-
ical Practice (GCP) guidelines, the Data Protection Act 
(1998), the Mental Capacity Act (2005), as well as the 
ICNARC CTU’s research policies and procedures.
dissemination
Results of this pilot study will be presented at local, 
national and international conferences and also published 
in peer-reviewed journals.
Participant confidentiality and data protection
No identifiable participant data will be required by the 
ICNARC CTU, as all follow-up data will be collected at 
participating sites. All participant data will be stored 
securely. ICNARC is registered under the Data Protec-
tion Act (1998), and all ICNARC CTU staff have under-
gone data protection and International Conference on 
Harmonisation (ICH) GCP training.
dIscussIon
We believe that there is an urgent need for high-quality 
clinical evidence to inform on the optimal targets of 
systemic oxygenation during paediatric critical illness. 
Inferences ‘up’ from extremely premature infants or 
‘down’ from adults are in conflict and unlikely to be 
valid in children because of age-related differences in the 
acute physiological responses to hypoxia/hyperoxia and 
distinct comorbidities.
A clinical trial comparing current (liberal) targets for 
systemic oxygenation with lower (conservative) targets in 
critically ill children is therefore required. This pilot study 
is a crucial step to understand if this is possible and also 
affords the opportunity to learn more about the biolog-
ical mechanisms underlying costs and benefits of oxygen 
therapy in children.
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